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SUMMARY
Pimecrolimus is a calcineurin inhibitor developed for the
topical therapy of inflammatory skin diseases, particularly
atopic dermatitis (AD). Pimecrolimus selectively targets T
cells and mast cells. Pimecrolimus inhibits T-cell proliferation,
as well as production and release of interleukin-2 (IL-2), IL-4,
interferon-g and tumour necrosis factor-a. Moreover, pime-
crolimus inhibits mast cell degranulation. In contrast to tacro-
limus, pimecrolimus has no effects on the differentiation,
maturation and functions of dendritic cells. In contrast to
corticosteroids, pimecrolimus does not affect endothelial cells
and fibroblasts and does not induce skin atrophy. Given the
low capacity of pimecrolimus to permeate through the skin, it
has a very low risk of systemic exposure and subsequent
systemic side-effects. In different randomised controlled trials,
topical pimecrolimus as cream 1% (Elidel) has been shown
to be effective, well tolerated and safe in both adults and
children with mild to moderate AD. In addition, pimecroli-
mus has been successfully used in inflammatory skin diseases
other than AD, including seborrheic dermatitis, intertriginous
psoriasis, lichen planus and cutaneous lupus erythematosus.
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INTRODUCT ION
For many years, topical corticosteroids have been the main-
stay of dermatological treatment for many inflammatory skin
diseases. Nowadays, the topical calcineurin inhibitors, pime-
crolimus and tacrolimus, provide an effective and safe alter-
native especially for long-term control of chronic
inflammatory diseases such as atopic dermatitis (AD). This
review focuses on the mechanism of the action of pimecroli-
mus, the evidence regarding the efficacy and safety of topical
pimecrolimus in AD and its use in ‘off-label’ skin conditions.
MECHANISM OF ACT ION
Pimecrolimus is a macrolactam immunomodulator belonging,
together with tacrolimus and cyclosporine, to the family of
calcineurin inhibitors. These drugs bind to cytoplasmic pro-
teins and the resulting complex binds calcineurin, inhibiting
its ability to dephosphorylate the nuclear factor of activated T
cells (NF-AT). The ligand for cyclosporine is cyclophilin,
whereas pimecrolimus and tacrolimus bind macrophilin-12,
also known as FK506-binding protein.
NF-AT is a nuclear transcription factor that facilitates the
transcription of several growth factor and inflammatory genes;
however, it must be phosphorylated to translocate into the
nucleus (1). Pimecrolimus shows a selective action on T cells
and mast cells as opposed to the more pleiotropic targets of
tacrolimus and corticosteroids (Table 1). The activation of T
cells and mast cells plays a crucial role in the pathogenesis of
many inflammatory skin diseases, including AD. Pimecrolimus
inhibits T-cell proliferation and production and the release of
several growth factors and pro-inflammatory cytokines includ-
ing interleukin-2 (IL-2), IL-4, interferon-g (IFN-g) and
tumour necrosis factor-a (TNF-a). Moreover, pimecrolimus
prevents mast cell release of pro-inflammatory mediators
including histamine, cytokines, tryptase and eicosanoids (2,3).
In contrast to tacrolimus and corticosteroids, pimecrolimus
does not affect the differentiation, maturation and functions
of dendritic cells and does not induce apoptosis of epidermal
Langerhans’ cells (4–6). In line with these findings, pimecro-
limus administered to mice suppresses only the elicitation
(but not the sensitisation) phase of contact hypersensitivity
to haptens, a T-cell–mediated immune reaction driven by
dendritic cells that represents a model of human allergic
contact dermatitis (7). In contrast to corticosteroids, pime-
crolimus and tacrolimus do not affect endothelial cells and
fibroblasts and, therefore, do not induce telangiectasia and
skin atrophy (8).
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Permeation of topical drugs through the skin leading to
uptake into the systemic circulation is generally not desired
and may, in some instances (e.g. in children, on extensive
medication of large skin areas), lead to systemic side-effects.
In the case of topical corticosteroids, such side-effects may
include hypothalamic-pituitary-adrenal axis suppression and
Cushing’s syndrome. The propensity of pimecrolimus to pass
through the skin is about 90 times lower than corticosteroids
and about nine times lower than tacrolimus (9). The differ-
ences related to skin permeation may be explained by the
distinct lipophilicity/hydrophilicity distribution within the
molecules, and the higher molecular weight of pimecrolimus
and tacrolimus (approximately 800 Da), compared with cor-
ticosteroids (approximately 470 Da). The intrinsic capability
of pimecrolimus and tacrolimus to cross the stratum corneum
is similar, whereas the further penetration is impaired in the
case of pimecrolimus. We can thus assume that the percuta-
neous absorption of pimecrolimus into systemic circulation is
not relevant clinically. Moreover, the more selective action of
pimecrolimus may account for a lower risk of systemic
immune suppression, thus offering a better safety margin
than other topical drugs.
P IMECROLIMUS IN ATOP IC DERMATIT IS
Atopic dermatitis is a chronic inflammatory skin disease
affecting 5–20% of children and 1–3% of adults (10,11).
The majority of cases begins in childhood, often in infancy.
AD runs a chronic, relapsing course and manifests as an itchy,
erythematous and scaly rash commonly on the face and skin
folds (neck, knees and elbows). AD is a heterogeneous disease
frequently associated with asthma and rhino-conjunctivitis.
AD has a significant impact on the quality of life of patients
and caregivers, causes sleep disturbances and affects patients’
social and school/work life. AD imposes a financial burden on
the health care system and even more on the individual for
both direct and indirect costs (12,13)
The pathogenesis of AD is complex with both genetic and
environmental factors playing important roles. Both these
components stimulate an excessive type 2 immune response
to allergens and skin inflammatory reactivity. Cutaneous
lesions may result from an immune response to allergens
and also from an abnormal cutaneous reactivity to irritants,
both favoured by epidermal barrier dysfunction (10).
The therapeutic approach to AD patients includes the
identification and elimination of triggering environmental
factors. The goal of treatment is to induce and maintain
remission. The therapy includes appropriate skin care, topical
glucocorticoids and topical calcineurin inhibitors. Pruritus is
only partially controlled by systemic H1-antihistamines.
Treatment with phototherapy and with systemic glucocorti-
coids and other immunosuppressives is restricted to patients
with severe disease.
Pimecrolimus is currently approved by the Food and Drug
Administration (FDA) and the European Medicines Agency
for short-term and intermittent long-term treatment of mild
to moderate AD in non-immunocompromised patients 2
years of age or older. Numerous double-blind, controlled
clinical trials proved the efficacy and safety of pimecrolimus
in AD.
Efficacy of Pimecrolimus in AD
Short-term studies. In two independent 6-week randomised
control trials (RCTs), treatment with pimecrolimus 1%
cream twice daily alleviated significantly signs and symptoms
of AD in children and adolescents as compared with its
emollient vehicle. At week 6, 35% of pimecrolimus-treated
patients were classified as clear or almost clear of disease
according to an Investigator Global Assessment (IGA). The
drug showed a rapid onset of action, with therapeutic effects
observed by the first visit on day 8 and further improvement
thereafter (14). The ethnic origin and the baseline disease
severity had no effect on treatment outcome (15). The effects
Table 1 Comparison between topical pimecrolimus, tacrolimus and corticosteroids
Pimecrolimus Tacrolimus Corticosteroids
Major cellular targets T cells, mast cells T cells, mast cells,
dendritic cells, eosinophils
T cells, mast cells, dendritic cells, endothelial cells,
fibroblasts, keratinocytes
Cytokines inhibited IL-2, IL-3, IL-4, IL-5,
IFN-g, TNF-a
IL-2, IL-3, IL-4, IL-5,
IFN-g, TNF-a
IL-2, IL-3, IL-4, IL-5, GM-CSF,
IFN-g, TNF-a, IFN-a
Blockade of dendritic cell functions – þ þþ
Apoptosis of dendritic cells – þ þþ
Suppression of the sensitisation
phase of contact hypersensitivity
– þ þ
Suppression of the elicitation
phase of contact hypersensitivity
þ þ þ
Skin penetration þ þþ þþþ
Atrophogenic potential – – þþþ
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of pimecrolimus compared with vehicle on sleep disturbances
were also evaluated. Although not significant after 3 weeks of
therapy, all trends suggested better sleep patterns in the group
treated with pimecrolimus cream (16).
An RCT compared pimecrolimus cream 1% with tacroli-
mus ointment 0.03% in paediatric patients with moderate to
severe AD. A total of 170 patients aged 2–17 years were
randomised into two treatment groups (pimecrolimus vs.
tacrolimus). The therapies were applied twice daily until
complete clearance of disease or until week 6. Regarding
efficacy, there were no statistically significant differences
between treatment groups in the proportion of patients
achieving clinical success (i.e. IGA or pruritus score of 0
or 1); however, IGA response rates were slightly higher in
the tacrolimus group. Application site reactions (ASRs) were
significantly more common and of longer duration in the
tacrolimus group than in the pimecrolimus group. The for-
mulation attributes of pimecrolimus were generally preferred
by patients or caregivers compared with tacrolimus. Local
viral or bacterial skin infections were infrequent (involving
no more than 3% of patients), and no major differences were
observed between treatment groups. This trial showed that
pimecrolimus cream 1% and tacrolimus ointment 0.03%
have a similar efficacy in the treatment of paediatric patients
with moderate to severe AD, but the pimecrolimus formula-
tion was generally preferred (17).
Long-term studies. In a 1-year, multicentre RCT involving
251 infants aged 3–23 months with AD, pimecrolimus cream
1% was compared with its vehicle in the long-term manage-
ment of mild to moderate AD. Topical treatment with pime-
crolimus significantly reduced the incidence of flares
compared with vehicle, with 68 vs. 30% of patients complet-
ing 6 months with no flares and 57 vs. 35% completing 12
months with no flares. These data suggest that the use of
pimecrolimus at the early signs and symptoms of AD signifi-
cantly modifies disease course by reducing the occurrence of
flares (18). This study was followed by an open-label exten-
sion of 1 year, in which the proportion of patients with no
flares increased over time to 85% (19). The potential of
pimecrolimus to prevent flares of AD requiring corticosteroid
therapy was evaluated also in adults. A 6-month study in
adults with moderate AD demonstrated that the early admin-
istration of pimecrolimus at the first signs of disease exacer-
bation prevented progression to flares and significantly
reduced, compared with emollients, the need for topical
corticosteroids in almost 60% of patients (20).
The long-term safety and efficacy of pimecrolimus in a
large adult population (n ¼ 658) were compared with topical
corticosteroids (0.1% triamcinolone acetonide for the trunk
and limbs and 1% hydrocortisone acetate for the face, neck
and intertriginous area). Medications were applied twice daily
to all affected areas until complete clearance of the inflamma-
tion was achieved and pruritus had ceased. In efficacy
measures, patients treated with corticosteroids responded bet-
ter than pimecrolimus-treated patients at all time points
except at the end of the study (after 13 months) when the
differences were not statistically significant. An interesting
distinction between the two groups was the proportion of
patients that discontinued the study prematurely for unsatis-
factory therapeutic effect, namely 36% of the patients
receiving pimecrolimus and 8% of those on corticosteroid
treatment. The decision of patients treated with pimecrolimus
to discontinue the study appears to correlate with the severity
of disease before starting therapy. Among patients receiving
pimecrolimus, the risk of discontinuation for the lack of
efficacy in patients with Eczema Area and Severity Index
(EASI) score >25 at baseline was 2.6 times higher than the
risk for patients with a baseline EASI score of 5–15, and the
risk for patients with a baseline EASI score <5 was about half
that of patients with a baseline EASI score of 5–15.
Therefore, severity of disease is a predictor of premature
discontinuation.
There were no statistically significant differences between
the two treatment groups in the global incidence of bacterial,
fungal and viral skin infections. However, in patients
with > 30% of the body surface area affected by AD, and
thus requiring more extensive medication, the incidence of
overall skin infections in the group receiving corticosteroids
was double that in the pimecrolimus group (21).
Safety of Pimecrolimus in AD
After subcutaneous or oral administration in mice, pimecro-
limus showed a lower potential of affecting immune responses
compared with tacrolimus (22). Indeed, patients with AD
treated with pimecrolimus cream 1% for up to 1 year showed
a normal response pattern to a range of common bacterial and
fungal antigens (23). Moreover, treatment of AD with pime-
crolimus cream 1% in early childhood for 2 years did not
interfere with the development of a normal immune response
to vaccinations (24).
Local side-effects of topical calcineurin inhibitors com-
monly reported by patients are feelings of warmth/burning/
stinging, increase of erythema or irritation and increased
itching. In a short-term study in paediatric patients, feeling
of warmth/burning/stinging was reported by 20% of patients,
whereas erythema/irritation and itching was reported by 8%.
All lasted less than 30 min (17). In a long-term study in
infants, there were no clinically significant differences
between the group receiving pimecrolimus and the group
receiving placebo with respect to the incidence of common
adverse events and skin infections (18).
In the long-term study conducted in adults, ASRs were
experienced by 46% of patients. In general, these events were
of mild to moderate severity in most cases and occurred early
in the treatment phase. In 50–60% of cases, ASRs started
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during the first 4 days of pimecrolimus application, resolved
within 7 days and were most frequently localised on the face
and neck. The most common ASR was burning sensation,
which occurred in 26% of the adult patients treated with
pimecrolimus.
Comparing the incidence of infections in adult patients
treated with pimecrolimus or vehicle, bacterial and fungal
infections occurred at similar frequencies in both groups.
However, viral infections, specifically herpes simplex infec-
tion, was more frequent in the pimecrolimus group (11%) vs.
vehicle (4%) (20). No patient developed eczema herpeticum.
Another critical concern is the potential risk of the develop-
ment of ultraviolet radiation (UVR)-mediated skin cancer.
The risk of photocarcinogenicity associated with pimecroli-
mus and exposure to sunlight was investigated in a standard
murine model. After 40 weeks of daily UVR exposure and
topical concomitant application of pimecrolimus, no increase
in the incidence of precancerous lesions was observed in
comparison with that in the vehicle-treated animals, giving
evidence for a low photocarcinogenic property of pimecroli-
mus (FDA/Center for Drug Evaluation and Research. Elidel
cream. Retrieved from http://www.fda.gov/cder/foi/nda/
2001/21-302). No phototoxic or photoallergic potential was
observed in healthy individuals.
Therapy with the calcineurin inhibitors and corticosteroids
may, on a theoretical basis, increase the risk of development
of non-cutaneous cancers, including lymphoma. There is no
evidence to indicate that any such increase in risk occurs with
topical therapy in humans, although significant systemic
immunosuppression in animals and humans does increase
cancer risk.
There are no conclusive data regarding the safety of
pimecrolimus during pregnancy. Pimecrolimus is excreted
in human milk; therefore, its use is not recommended dur-
ing nursing.
P IMECROL IMUS IN OTHER SKIN DISEASES
Topical pimecrolimus may be useful in the treatment of
chronic inflammatory skin diseases other than AD. The effi-
cacy of pimecrolimus according to the level of evidence is
presented in Table 2. Controlled trials have provided evi-
dence of efficacy of topical pimecrolimus in intertriginous
psoriasis (25), seborrheic dermatitis (26) and chronic hand
dermatitis (27). In addition, pimecrolimus has been found to
be effective in oral lichen planus (28,29) and cutaneous lupus
erythematosus (30). Case reports of clinical success have been
reported for cutaneous lichen planus (31), vitiligo (32) and
chronic graft-vs.-host disease (33).
Psoriasis
The efficacy of pimecrolimus in the therapy of inverse psor-
iasis has been documented in a randomised, double-blind,
placebo-controlled clinical trial involving 57 adult patients.
A large proportion (i.e. 71%) of patients treated with pime-
crolimus was assessed as clear or almost clear by the investi-
gator after therapy for 8 weeks; however, the benefits of the
therapy were observed as early as day 3. Only one case of mild
application site paresthesia suspected to be related to the
topical pimecrolimus was reported, whereas skin atrophy,
telangiectasia and secondary bacterial or Candida skin infec-
tion were not reported during the study. In another random-
ised, double-blind study, the efficacy of an ointment
formulation of pimecrolimus 1% was compared with its vehi-
cle, with 0.005% calcipotriol and with 0.05% clobetasol-
17-propionate in the treatment of plaque psoriasis. At day
21, pimecrolimus ointment applied without occlusion was
more effective than its vehicle, but significantly less effective
than calcipotriol and clobetasol in reducing erythema, indur-
ation and scaling scores (34).
Table 2 Pimecrolimus in inflammatory skin diseases
Established efficacy Likely beneficial Possibly beneficial
Atopic dermatitis (1þþ) (mild to moderate) Seborrheic dermatitis (2–) Vitiligo (3)
Intertriginous psoriasis (1þ) Anogenital lichen sclerosus and atrophicus (3)
Lupus erythematosus (3)
Oral and cutaneous lichen planus (3)
Dermatomyositis (3)
Chronic graft-vs.-host disease (3)
Level of evidence according to the Scottish Intercollegiate Guidelines Network (37):
(1þþ) High-quality meta-analyses, systematic reviews of randomised control trials (RCTs) or RCTs with a very low risk of bias.
(1þ) Well-conducted meta-analyses, systematic reviews of RCTs or RCTs with a low risk of bias.
(1–) Meta-analyses, systematic reviews or RCTs or RCTs with a high risk of bias.
(2þþ) High-quality systematic reviews of case–control or cohort studies or high-quality case–control or cohort studies with a very low risk of confounding, bias
or chance and a high probability that the relationship is causal.
(2þ) Well-conducted case–control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal.
(2–) Case–control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal.
(3) Non-analytic studies, e.g. case reports and case series.
(4) Expert opinion.
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Seborrheic Dermatitis
The efficacy of pimecrolimus in the treatment of seborrheic
dermatitis has been compared with a potent corticosteroid in
an open-label clinical trial involving 22 adult patients (26).
The efficacy of the two different treatments in reducing
erythema, scaling and pruritus was approximately the same.
Both drugs reduced symptoms completely at day 9, with
betametasone acting faster than pimecrolimus. However,
following discontinuation of treatment, relapses were
observed more frequently and were more severe in the beta-
methasone than in the pimecrolimus group.
Chronic Hand Dermatitis
In a large, randomised, double-blind, vehicle-controlled study
involving 294 adults patients with chronic hand dermatitis,
pimecrolimus induced a complete or almost complete clear-
ance in 30% of patients after 22 days of continuous therapy
including overnight occlusion (27). The proportion of
patients achieving treatment success was greater in the active
group compared with the placebo group, but the difference
was not statistically significant. Patients without palmar
involvement responded better to treatment than those with-
out palmar involvement, perhaps because the thickness of the
stratum corneum on the palms could impair penetration of
the drug. The overnight occlusion in subjects with chronic
hand dermatitis does not lead to a massive permeation
through skin, because the pimecrolimus blood concentration
was consistently low through the study and, in 74% of cases,
below the limit of quantification (0.1 ng/ml) (35).
Oral Pimecrolimus
Testing the efficacy of oral pimecrolimus in patients with
psoriasis or AD is underway. Data currently available show
that pimecrolimus is effective in the therapy of chronic plaque
psoriasis in a dose-dependent manner. At week 12, the
median reduction of the Psoriasis Area and Severity Index
(PASI) score was 80 and 58% in 60 and 40 mg/day dosage
groups, respectively. The drug showed a good safety profile in
short-term treatment; the only consistent side-effect recorded
was a transient feeling of warmth on the upper chest occur-
ring 40 min after ingesting the medication and lasting about
90 min. Moreover, with short-term treatment, pimecrolimus
had no significant effect on laboratory measures nor did it
affect various immunologic parameters. Intradermal testing
for delayed hypersensitivity reactions to recall antigens
showed no significant changes after the course of pimecroli-
mus therapy (36). The long-term efficacy, time-to-relapse
after discontinuation and the long-term safety await further
studies.
CONCLUS IONS
Pimecrolimus cream appears an effective and safe treat-
ment option for the treatment of AD, especially when
the disease is mild to moderate and affects the face and
neck regions. Moreover, if the drug is applied at the first
signs of exacerbation of AD, it prevents flare progression,
modifying the course of the disease and reducing the need
for topical corticosteroids. In infants and children, a better
control of AD may reduce the risk of subsequent develop-
ment of asthma and/or rhinitis (atopic march). Finally,
pimecrolimus may well work in other inflammatory skin
diseases particularly when lesions are not keratotic and are
localised on the face or skin folds (where corticosteroids
are more likely to induce side-effects). Examples of such
conditions include seborrheic dermatitis and intertriginous
psoriasis.
REFERENCES
1 Marsland AM, Griffiths CE. The macrolide immunosuppres-
sants in dermatology: mechanisms of action. Eur J Dermatol
2002; 12: 618–22.
2 Grassberger M, Steinhoff M, Schneider D, Luger TA.
Pimecrolimus – an anti-inflammatory drug targeting the skin.
Exp Dermatol 2004; 13: 721–30.
3 Graham-Brown RAC, Grassberger M. Pimecrolimus: a review of
pre-clinical and clinical data. Int J Clin Pract 2003; 57: 319–27.
4 Hoetzenecker W, Meingassner JG, Ecker R et al. Corticosteroids
but not pimecrolimus affect viability, maturation and immune
function of murine epidermal Langerhans cells. J Invest Dermatol
2004; 122: 673–84.
5 Kalthoff FS, Chung J, Musser P, Stuetz A. Pimecrolimus does
not affect the differentiation, maturation and function of human
monocyte-derived dendritic cells, in contrast to corticosteroids.
Clin Exp Immunol 2003; 133: 350–9.
6 Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epider-
mal Langherans’ cells are targets for the immunosuppressive
macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001;
107: 345–52.
7 Meingassner JG, Fahrngruber H, Bavandi A. Pimecrolimus
inhibits the elicitation phase but does not suppress the sensitiza-
tion phase in murine contact hypersensitivity in contrast to
tacrolimus and cyclosporine A. J Invest Dermatol 2003; 121: 231.
8 Queille-Roussel C, Paul C, Duteil L et al. The new topical
ascomycin derivative SDZ ASM 981 does not induce skin atro-
phy when applied to normal skin for 4 weeks: a randomized,
double-blind controlled study. Br J Dermatol 2001; 144:
507–13.
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